New applications based on KiOmedine-CsU®, the world’s first GMP ultra-pure chitosan of non-animal origin
Recently medical and pharma professionals read several articles about chitosan in pharma and medical industry including some highlighting brand new applications based on KiOmedine-CsU®, the unique GMP ultra-pure animal-free chitosan.
Since several years, KitoZyme is pushing its technology platform KiOmedine® by developing its expertise around it or improving the characteristics and safety profile of the KiOmedine®product range. A tight management of the molecular characteristics of ultra-pure chitosan was established, enabling for the first time to supply an ultra-pure GMP animal-free chitosan now in 4 different molecular weights, including the latest advancement of a low molecular weight version. The molecular weight of KiOmedine-CsU® is now ranged from 40,000 to 200,000, with narrow polydispersity and high batch-to-batch consistency.
This extended range gives the opportunity to medical and pharmaceutical companies to screen variable molecular characteristics for optimum and consistent performance, providing opportunities for customized specification and greater differentiation of the final formulations. Freshly Novartis has published the use of the lowest molecular weight KiOmedine-CsU® to create various polyplexes for the delivery of siRNA1.
Besides, the University of Liège in Belgium recently developed a 3-D dressing composed of chitosan nanofibers and a porous chitosan membrane (made with KiOmedine-CsU®) that promises to shorten the healing time of skin wounds by stimulating migration, invasion, and proliferation of the relevant cutaneous resident cells. When used as a dressing covering full-thickness skin wounds in mice, chitosan nanofibrils induced a faster regeneration of both the epidermis and dermis compartments. The study illustrates the critical importance of the nanofibrillar structure of chitosan devices for their full biocompatibility, and demonstrates the significant beneficial effect of chitosan as a wound-healing biomaterial2.
Another breakthrough in the medical device area is the development of hydrogel beads for intra-articular injection in knee arthritis indications, based on KiOmedine-CsU®. This innovation is now patented and is subject to the creation of a new spin-off called Synolyne.
The safety and efficacy of KiOmedine-CsU® was proven in other formulations and therapeutic strategies, such as nanoparticles, tubes, fibres, scaffolds, viscous solutions, and other surgical implants. The availability of KiOmedine-CsU® is clearly triggering new developments of chitosan-based pharmaceutical and medical device applications beyond topical and haemostatic use. The KiOmedine® range is available from KitoZyme and from Sigma-Aldrich for research purposes.
1 Holzerny et al, J Control Release. 2012 Jan 30;157(2):297-304
2 Tchemtchoua et al, Biomacromolecules 2011, 12, 3194–3204